The Uninvited Guests: How Long COVID Awakens a Hidden Army of Pathogens

What if the virus that infected you was only the beginning?

Five years into the Long COVID crisis, researchers have been laser-focused on SARS-CoV-2 — hunting for viral reservoirs, measuring spike protein in blood, testing antivirals. But a growing body of evidence suggests the real drivers of persistent illness may not be COVID at all. They're the passengers it let in.

When SARS-CoV-2 tears through your body, it doesn't just damage tissue and trigger inflammation. It dismantles the barriers that keep your internal ecosystem in check. The gut lining loosens. The immune system falters. And organisms that have lived quietly inside you for years — fungi in your gut, dormant viruses in your B cells, bacteria held at bay by a healthy microbiome — suddenly find the doors wide open.

Three independent lines of evidence now point to these uninvited guests as central players in Long COVID. And for the first time, clinical trials are showing that targeting them actually works.

The Leaky Barrier

Your gut is a fortress — a single layer of cells sealed with tight junctions that separate trillions of microorganisms from your bloodstream. When SARS-CoV-2 infects gut epithelial cells through ACE2 receptors, it damages those junctions. The molecular evidence is clear: a protein called zonulin, which regulates tight junction permeability, is significantly elevated in Long COVID patients — 4.76 mg/mL versus 3.37 in controls. Each unit increase in zonulin raises the odds of developing PASC by 44%.

The fence is broken. And what comes through changes everything.

Kingdom One: The Fungi

In 2022, a team at the Wistar Institute led by Leila Giron and Mohamed Abdel-Mohsen made a striking discovery. They measured β-D-glucan — a component of fungal cell walls — in the blood of Long COVID patients. What they found was staggering.

Fungi — primarily Candida species that normally reside harmlessly in the gut — were crossing into the bloodstream. Once there, β-D-glucan binds to Dectin-1 receptors on immune cells, activating the Syk kinase cascade and ultimately firing up NF-κB, one of the body's most powerful inflammatory switches. The result: systemic inflammation driven not by SARS-CoV-2 itself, but by fungal products that should never have reached the blood.

Even more concerning: the Wistar team found that Long COVID blood contained elevated quinolinic acid, a potent neurotoxin and NMDA receptor agonist. Tryptophan metabolism was being shunted toward neurotoxic metabolites — and the fungal markers correlated with these neurological signatures. The brain fog that haunts Long COVID patients may be, in part, a fungal product.

Later work from Weill Cornell and published in Nature in 2023 added a disturbing twist: gut Candida during COVID doesn't just translocate — it primes neutrophil precursors in the bone marrow, creating a heightened immune memory that persists for at least a year after infection. The fungi leave a lasting mark on the immune system even after they're gone.

Kingdom Two: The Dormant Virus

Long before SARS-CoV-2 existed, most of us were already carrying passengers. By adulthood, roughly 95% of people harbor Epstein-Barr virus (EBV) in dormant B cells — a herpesvirus that causes mononucleosis and then, typically, never bothers you again.

Until COVID wakes it up.

Multiple studies have documented EBV reactivation in Long COVID: 50% of LC patients show EBV DNA in throat swabs versus 20% in non-LC controls. A 2025 study of 140 patients found that 28.6% of those with persistent fatigue had serological evidence of EBV reactivation, compared with 11.3% of controls. Across cohorts, EBV reactivation roughly doubles the odds of fatigue and brain fog in Long COVID.

But for years, nobody could explain why COVID was waking up EBV. The virus doesn't directly infect the B cells where EBV sleeps. Inflammatory cytokines didn't seem to be the trigger either.

Then in August 2025, Ling and Li published a paper in Emerging Microbes & Infections that solved the puzzle. The trigger isn't the virus. It's heme.

When COVID damages red blood cells and tissues, free heme is released into the bloodstream. Ling and Li showed that heme — dose-dependently — upregulates the lytic genes BZLF1, BMRF1, and BFRF3 in EBV-infected B cells, flipping the virus from dormant to active. Heme levels are elevated in both acute COVID and in patients six months later. The virus wakes not because SARS-CoV-2 attacks its hiding place, but because the collateral damage of COVID puts the trigger in the lock.

This finding was independently confirmed in 2026 by the massive IMPACC multiomics study (Gabernet et al., JCI), which found elevated heme metabolism transcripts in patients who developed Long COVID — without even looking for EBV. Two independent teams, two independent methods, one convergent finding.

Kingdom Three: The Bacteria

The third kingdom is the most familiar: the gut microbiome. COVID doesn't just weaken the gut barrier — it reshapes the bacterial community behind it.

In Long COVID patients, beneficial species like Faecalibacterium prausnitzii and Bifidobacterium — key producers of short-chain fatty acids that nourish the gut lining — are depleted. Meanwhile, pro-inflammatory species like Ruminococcus gnavus and Veillonella expand. The result is a dysbiotic community that produces fewer protective metabolites and more inflammatory ones.

With the gut barrier already compromised by COVID, bacterial products — particularly lipopolysaccharide (LPS), a potent endotoxin — can translocate into the bloodstream. LPS crosses the blood-brain barrier and activates microglia, the brain's resident immune cells, contributing to neuroinflammation. This is the gut-brain axis in overdrive.

The Vicious Cycle

What makes this framework so compelling — and so difficult to treat — is that the three kingdoms don't act in isolation. They amplify each other in a self-reinforcing loop.

SARS-CoV-2 exhausts T cells and damages the gut barrier. Fungi translocate and prime neutrophils. Heme from tissue damage wakes dormant EBV. Bacterial dysbiosis produces endotoxins that cross into the brain. The resulting inflammation further weakens the gut barrier, further exhausts the immune system, and releases more heme — feeding the cycle.

This is why single-mechanism treatments keep failing. Antivirals targeting SARS-CoV-2 can't suppress EBV (which is reactivated by heme, not by the virus). Anti-inflammatories dampen symptoms but don't seal the gut barrier. Antibiotics don't touch fungi. Each treatment addresses one kingdom while leaving the others to sustain the loop.

Fighting Back: Two Trials That Worked

The co-infection framework isn't just a theory. Two randomized controlled trials — a rarity in Long COVID — have shown that targeting these pathways produces real clinical improvement.

The K2/D3 trial (Atieh et al., Nutrients 2025) gave 98 Long COVID patients vitamin D3 (2000 IU) plus vitamin K2 (MK-7, 240 µg) daily for 24 weeks. The treatment group saw β-D-glucan levels drop by 40.3 pg/mL versus 15.8 in controls (p=0.03) — directly measuring reduced fungal translocation. More importantly, the proportion of patients meeting the RECOVER Long COVID Index threshold decreased 7.1% in the treatment group while increasing 7.2% in controls (p=0.01). This is the first RCT to show that reducing fungal translocation correlates with clinical improvement in Long COVID.

The SIM01 trial (Ng et al., Lancet Infectious Diseases 2023) was larger and arguably more impressive. 463 Long COVID patients received a synbiotic formula containing three Bifidobacterium species plus prebiotic fibers for six months. The results were striking across nearly every symptom domain: fatigue improved with an odds ratio of 2.27, concentration problems 2.64, memory difficulties 1.97, gastrointestinal symptoms 2.00, and general unwellness 2.36. Microbiome analysis confirmed the gut bacterial community became more diverse, with increased short-chain fatty acid producers.

Neither trial is a cure. But together they demonstrate something important: the co-infection pathways in Long COVID are not just observational curiosities. They are modifiable.

What's Missing — and What's Coming

Despite the evidence for fungal translocation in 74% of Long COVID patients, no clinical trial has tested antifungal agents for the condition. This is perhaps the most glaring gap in the current treatment landscape.

The most promising near-term development is larazotide acetate (AT1001), a zonulin receptor antagonist that tightens gut tight junctions. A Phase 2a trial (NCT05747534) is actively recruiting 48 Long COVID patients. The drug already showed rapid clearance of spike protein from the blood in children with MIS-C, published in Science Translational Medicine in 2025. If larazotide can seal the gut barrier, it could cut off the supply line for both fungal and bacterial translocation simultaneously — addressing two kingdoms with one mechanism.

For EBV, the IMC-2 trial at the Bateman Horne Center is testing valacyclovir combined with celecoxib in patients with herpesvirus-driven Long COVID. PolyBio's Truvada + Maraviroc trial at Mount Sinai completed enrollment in early 2026 with results pending. But the heme→EBV mechanism suggests a fundamentally different approach may be needed: rather than targeting the reactivated virus, controlling heme levels or heme-mediated signaling could prevent reactivation in the first place.

The Framework Shift

The co-infection model doesn't replace existing explanations for Long COVID — viral persistence, autoimmunity, mitochondrial dysfunction. It completes them. As a 2025 RECOVER perspective led by Timothy Henrich and Adolfo García-Sastre put it in eLife: COVID commits "immunity theft," leaving the body unable to manage the microbial ecosystem it has coexisted with for years.

The therapeutic implications are clear. Single-target approaches will continue to fail against a multi-kingdom problem. What's needed are combination strategies: seal the barrier, restore the microbiome, suppress reactivated viruses, and quiet the inflammatory cascade — ideally simultaneously. The K2/D3 and SIM01 trials prove these pathways are modifiable. The question now is whether the field will design trials bold enough to target more than one at a time.

Long COVID may not be one disease with one cause. It may be a cascade of uninvited guests, each adding fuel to a fire the body can no longer extinguish. The good news: we now know their names.